Quarterly ResultMay 27, 2026, 08:02 AM
Mesa Labs Q4 Revenue +2.6%, FY26 Revenue +3.4%; Debt Reduced
AI Summary
Mesa Laboratories reported mixed results for its fourth fiscal quarter and full fiscal year 2026. For Q4, revenues increased 2.6% to $63.7 million, while the company posted a GAAP net loss of $4.1 million. Full fiscal year 2026 revenues grew 3.4% to $249.1 million, with GAAP net income of $6.7 million. The company also repaid $14.7 million in debt during Q4, reducing its net leverage ratio to 2.11, and expects overall revenues to return to positive core organic growth in 1Q27.
Key Highlights
- Q4 2026 revenues increased 2.6% to $63.7 million.
- FY 2026 revenues increased 3.4% to $249.1 million.
- Q4 2026 GAAP net loss was $4.1 million, or $(0.75) per diluted share.
- FY 2026 GAAP net income was $6.7 million, or $1.21 per diluted share.
- Non-GAAP adjusted operating income (AOI) excluding unusual items rose 49.2% in Q4 and 11.9% in FY26.
- Repaid $14.7 million of debt in Q4, reducing Total Net Leverage Ratio to 2.11.
- Sterilization and Disinfection Control (SDC) revenues grew 17.7% in Q4.
- Biopharmaceutical Development (BPD) revenues declined 29.9% in Q4 due to execution and export controls.
Price Impact
More from MLAB